Mega Lifesciences PCL
SET:MEGA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (16.5), the stock would be worth ฿46.21 (39% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.9 | ฿33.25 |
0%
|
| 3-Year Average | 16.5 | ฿46.21 |
+39%
|
| 5-Year Average | 17 | ฿47.46 |
+43%
|
| Industry Average | 13.6 | ฿38.12 |
+15%
|
| Country Average | 12.6 | ฿35.31 |
+6%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
M
|
Mega Lifesciences PCL
SET:MEGA
|
29B THB | 11.9 | 15.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 145.6 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 35.4 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 19.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 25 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 43.2 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 22.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 11.7 | 16.8 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.8 |
| Median | 12.6 |
| 70th Percentile | 17.3 |
| Max | 6 871.7 |
Other Multiples
Mega Lifesciences PCL
Glance View
Mega Lifesciences Public Co. Ltd. engages in the manufacture, market, sale, and distribution of pharmaceutical, nutraceutical products, and consumer goods. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2013-11-19. The firm's products include complimentary medicines, over-the-counter (OTC) medicines and prescription medicines to both domestic and international markets. The company distributes products under Maxxcare brand covering prescription pharmaceutical products, OTC drugs and other consumer products. The firm also offers nutritional products, prescription pharmaceutical products and OTC drugs under Mega We Care brand. In addition, the Company operates as an original equipment manufacturer (OEM) for various products including health supplements, pharmaceutical, herbal products, vitamins and minerals, among others.
